Phase 3 study results of isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) versus VRd for transplant-ineligible patients with newly diagnosed multiple myeloma (IMROZ).

被引：0

作者：

Facon, Thierry

Dimopoulos, Meletios Athanasios

Leleu, Xavier P.

Beksac, Meral

Pour, Ludek

Hajek, Roman

Liu, Zhuogang

Minarik, Jiri

Moreau, Philippe

Romejko-Jarosinska, Joanna

Spicka, Ivan

Vorobyev, Vladimir I.

Cavo, Michele

Goldschmidt, Hartmut

Martin, Thomas G.

Manier, Salomon

Bregeault, Marie-France

Mace, Sandrine

Berthou, Christelle

Orlowski, Robert Z.

机构：

[1] Univ Lille, CHU Lille, Lille, France

[2] Natl & Kapodistrian Univ Athens, Sch Med, Dept Clin Therapeut, Athens, Greece

[3] CHU, Serv Hematol & Therapie Cellulaire, Poitiers, France

[4] CIC Inserm 1402, Poitiers, France

[5] Ankara Univ, Dept Hematol, Ankara, Turkiye

[6] Istinye Univ, Ankara Liv Hosp, Ankara, Turkiye

[7] Univ Hosp Brno, Brno, Czech Republic

[8] China Med Univ, Shengjing Hosp, Shenyang, Peoples R China

[9] Palacky Univ Olomouc, Olomouc, Czech Republic

[10] Univ Hosp Olomouc, Olomouc, Czech Republic

[11] Univ Hosp Hotel Dieu, Nantes, France

[12] Marie Sklowdoska Curie Natl Res Inst Oncol, Warsaw, Poland

[13] Charles Univ Prague, Prague, Czech Republic

[14] Gen Hosp Prague, Prague, Czech Republic

[15] SP Botkin Moscow City Clin Hosp, Moscow, Russia

[16] Univ Bologna, IRCCS Azienda Osped Univ Bologna, Ist Ematol Seragnoli, Bologna, Italy

[17] Univ Hosp Heidelberg, Heidelberg, Germany

[18] Univ Calif San Francisco, San Francisco, CA USA

[19] Univ Hosp Ctr Lille, Lille, France

[20] Sanofi R&D, Vitry Sur Seine, France

[21] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

7500

引用

页数：1